Aberrant Promoter Methylation in Serium DNA as a Biomarker for Prostate Cancer

摘要

In the United States, prostate cancer has become the second most frequently diagnosed neoplasm and the second leading cause of cancer mortality in men. The main objective of this study is to develop a serum-based test for prostate cancer using DNA methylation of one or more candidate genes to improve the predictive value of prostate cancer screening, which is currently based on PSA > 4 ng/ml and/or abnormal DRE. Candidate genes include pi-class glutathione s-transferase (GSTP1), E-cadherin (ECAD), retinoic acid receptor -2 (RARB), and ras association domain family 1 protein isoform 1A (RASSF1A). 46 patients were enrolled in the study for the reporting period. DNA extracted from the serum of these patients was bisulfite treated and analyzed by MSPCR. For this, we optimized the MS-PCR conditions for analysis of methylation of candidate genes proposed in the study. We have summarized the histopathological diagnosis along with the methylation status of the candidate genes. However we are not able to report any outcome of the study since 46 samples are not sufficient for conducting statistical analysis.